Education
About Us
Working with TipRanks
Follow Us
Quanterix Corporation (QTRX)
NASDAQ:QTRX
QTRX Stock Chart & Stats
$5.29
-$0.25(-2.12%)
At close: 4:00 PM EST
$5.29
-$0.25(-2.12%)
Day’s Range― - ―
52-Week Range$4.05 - $15.67
Previous CloseN/A
Volume125.22K
Average Volume (3M)509.80K
Market Cap
$242.09M
Enterprise Value$33.00M
Total Cash (Recent Filing)$261.17M
Total Debt (Recent Filing)$35.53M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Nov 10, 2025EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.77
Shares Outstanding46,465,916
10 Day Avg. Volume461,526
30 Day Avg. Volume509,801
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.14
Enterprise Value/Revenue0.26
Enterprise Value/Gross Profit0.47
Enterprise Value/Ebitda-0.39
Forecast
1Y Price Target
$5.92Price Target Upside11.91% Upside
Rating ConsensusHold
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Cost SynergiesThe company is targeting significant cost synergies of $85M by the first quarter of 2026, with $65M of cost actions already undertaken.
Pricing StrategyCLFS determinations add confidence in attractive pricing for the nascent AD Dx market, highlighting the significant pricing premium for multi-marker assays.
Technology AdvancementsThe Akoya acquisition, progress in diagnostics and upcoming launch of the Simoa One instrument should drive stronger performance over time.
Bears Say
Growth ConcernsQTRX updated its revenue guidance to a lower range of $100M-$105M, raising concerns about future growth potential.
Market CompetitionQTRX is starting to lag behind competitors, with Fujirebio's BBM already FDA approved, and QTRX does not expect FDA approval until 2026.
Revenue PerformanceTotal revenue of $24.5M fell short of already lowered expectations, with significant declines in both academic and pharma sectors.
Quanterix News
QTRX FAQ
What was Quanterix Corporation’s price range in the past 12 months?
Quanterix Corporation lowest stock price was $4.05 and its highest was $15.67 in the past 12 months.
What is Quanterix Corporation’s market cap?
Quanterix Corporation’s market cap is $242.09M.
When is Quanterix Corporation’s upcoming earnings report date?
Quanterix Corporation’s upcoming earnings report date is Nov 10, 2025 which is in 5 days.
How were Quanterix Corporation’s earnings last quarter?
Quanterix Corporation released its earnings results on Aug 07, 2025. The company reported -$0.77 earnings per share for the quarter, missing the consensus estimate of -$0.422 by -$0.348.
Is Quanterix Corporation overvalued?
According to Wall Street analysts Quanterix Corporation’s price is currently Undervalued.
Does Quanterix Corporation pay dividends?
Quanterix Corporation does not currently pay dividends.
What is Quanterix Corporation’s EPS estimate?
Quanterix Corporation’s EPS estimate is -0.46.
How many shares outstanding does Quanterix Corporation have?
Quanterix Corporation has 46,465,916 shares outstanding.
What happened to Quanterix Corporation’s price movement after its last earnings report?
Quanterix Corporation reported an EPS of -$0.77 in its last earnings report, missing expectations of -$0.422. Following the earnings report the stock price went down -13.793%.
Which hedge fund is a major shareholder of Quanterix Corporation?
Currently, no hedge funds are holding shares in QTRX
Quanterix Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.92 (11.91% Upside)
$5.92 (11.91% Upside)
Hedge Fund Trend
Decreased
By 142.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $19.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 5.4%
Last 30 Days ▼ 5.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.83%
12-Months-Change
Fundamentals
Return on Equity
-22.27%
Trailing 12-Months
Asset Growth
-9.69%
Trailing 12-Months
Company Description
Quanterix Corporation
Quanterix Corporation (QTRX) is a biotechnology company that focuses on advancing the field of precision medicine through its innovative technology platform. The company specializes in ultra-sensitive biomarker detection and analysis, enabling researchers and clinicians to better understand and diagnose diseases. Quanterix operates primarily in the life sciences sector, offering products and services that include their Simoa (Single Molecule Array) technology, which allows for the measurement of low-abundance biomarkers in various applications such as oncology, neurology, and cardiology.
QTRX Company Deck
QTRX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of strategic achievements and significant challenges. The company highlighted strong strategic moves and synergies following the Akoya acquisition, a stable consumables revenue stream, and expansion into new market segments. However, these positives were overshadowed by considerable revenue declines, particularly in academic and pharma sales, alongside increased operating expenses and a significant drop in gross margin. The company's focus on long-term growth and cost savings offers a positive outlook, but current financial challenges are significant.View all QTRX earnings summariesQTRX Stock 12 Month Forecast
Average Price Target
$5.92
▲(11.91% Upside)
Technical Analysis
Viemed Healthcare
―
Nano-X Imaging
―
Outset Medical
―
908 Devices
―
TriSalus Life Sciences
―
Ownership Overview
7.35% Insiders
14.80% Mutual Funds
2.82% Other Institutional Investors
65.18% Public Companies and Individual Investors